This strategy focuses on efficiently generating immature, genetically correct, skeletal muscle cells from iPS (induced pluripotent stem) cells and then transplanting them into the muscles of individuals with Duchenne. Once transplanted, the cells integrate into the cells and generate fully functional muscle cells.
This compound is in preclinical research, meaning it has not yet advanced to clinical trials.
This program is sponsored by the University of Minnesota.
